Maze Therapeutics, Inc.
MAZE
$41.49
$4.2211.32%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.09M | -33.68M | -32.79M | -29.58M | -24.75M |
| Total Depreciation and Amortization | 571.00K | 649.00K | 684.00K | 705.00K | 788.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.37M | 4.02M | 4.01M | 5.39M | 5.99M |
| Change in Net Operating Assets | 501.00K | -1.04M | -1.43M | 1.03M | -5.23M |
| Cash from Operations | -24.64M | -30.05M | -29.52M | -22.45M | -23.21M |
| Capital Expenditure | -68.00K | -393.00K | -299.00K | -605.00K | -103.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -66.82M | -- | -- | -- | -- |
| Cash from Investing | -66.88M | -393.00K | -299.00K | -605.00K | -103.00K |
| Total Debt Issued | -- | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 143.76M | 612.00K | 127.88M | 63.00K | 226.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 70.79M | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -500.00K | -594.00K | -2.38M |
| Cash from Financing | 143.76M | 612.00K | 127.38M | 70.26M | -2.15M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 52.23M | -29.83M | 97.56M | 47.21M | -25.46M |